Allakos Inc. (ALLK)

NASDAQ: ALLK · IEX Real-Time Price · USD
6.25
+0.13 (2.12%)
At close: Oct 3, 2022 4:00 PM
6.10
-0.15 (-2.40%)
After-hours: Oct 3, 2022 7:59 PM EDT
2.12%
Market Cap 342.78M
Revenue (ttm) n/a
Net Income (ttm) -403.22M
Shares Out 54.84M
EPS (ttm) -7.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 953,349
Open 6.19
Previous Close 6.12
Day's Range 5.74 - 6.28
52-Week Range 2.54 - 112.87
Beta 0.65
Analysts Hold
Price Target 6.69 (+7.0%)
Earnings Date Nov 7, 2022

About ALLK

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (A... [Read more...]

Industry Biotechnology
IPO Date Jul 19, 2018
CEO Robert Alexander
Employees 192
Stock Exchange NASDAQ
Ticker Symbol ALLK
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 17 analysts, the average rating for ALLK stock is "Hold." The 12-month stock price forecast is 6.69, which is an increase of 7.04% from the latest price.

Price Target
$6.69
(7.04% upside)
Analyst Consensus: Hold
Stock Forecasts

News

3 Healthcare Stocks to Sell Before They Die

The Fed's key interest rate target now stands at 3%-3.25%, way up from 0%-0.25% at the beginning of the year. That means, for all companies, borrowing money is becoming much more expensive.

Other symbols: IBIOTDOC
3 days ago - InvestorPlace

Why Is Allakos (ALLK) Stock Soaring 25% Today?

On Monday, biotechnology firm Allakos (NASDAQ: ALLK ) announced a public offering that raised gross proceeds of approximately $150 million, sending ALLK stock soaring 25% in the morning session before p...

2 weeks ago - InvestorPlace

Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria...

Top-line Phase 2b results expected in the second half of 2023 Top-line Phase 2b results expected in the second half of 2023

3 weeks ago - GlobeNewsWire

Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis

– Lirentelimab met histologic co-primary endpoint but missed symptomatic co-primary endpoint –

3 weeks ago - GlobeNewsWire

Why Allakos Stock Is on Fire Today

Investors appear to be getting into position ahead of a major upcoming catalyst.

1 month ago - The Motley Fool

Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results

SAN CARLOS, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inf...

1 month ago - GlobeNewsWire

Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors

SAN CARLOS, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inf...

2 months ago - GlobeNewsWire

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Manage...

Los Angeles, California--(Newsfile Corp. - June 15, 2022) -  The Schall Law Firm, a national shareholder rights litigation firm, announces it is investigating potential breaches of fiduciary duties by t...

3 months ago - Newsfile Corp

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Managemen...

Los Angeles, California--(Newsfile Corp. - June 14, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces it is investigating potential breaches of fiduciary duties by th...

3 months ago - Newsfile Corp

INVESTIGATION NOTICE: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Management of Al...

Los Angeles, California--(Newsfile Corp. - June 13, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces it is investigating potential breaches of fiduciary duties by th...

3 months ago - Newsfile Corp

Allakos Provides Business Update and Reports First Quarter 2022 Financial Results

REDWOOD CITY, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and in...

4 months ago - GlobeNewsWire

Why Allakos Stock Sank 17.3% in February

The biotech stock has lost roughly 96% of its value over the last year.

6 months ago - The Motley Fool

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and ...

7 months ago - GlobeNewsWire

12 biotech stocks to consider buying now as prospects for the sector brighten this year

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double

7 months ago - Market Watch

Allakos Inc. (ALLK) Flat As Market Gains: What You Should Know

Allakos Inc. (ALLK) closed at $6.54 in the latest trading session, marking no change from the prior day.

7 months ago - Zacks Investment Research

Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Allakos Inc. (ALLK) closed at $6.81, marking a -0.58% move from the previous day.

8 months ago - Zacks Investment Research

5 Important Investing Lessons From Allakos' Price Collapse

ALLK stock is a gamble now even after falling about 85% off its 52-week high. Allakos' slide offers investors with a learning opportunity.

8 months ago - InvestorPlace

Allakos Is a Cautionary Tale of Biopharmaceutical Investing

ALLK stock dropped off a cliff following disappointing study results, which illustrates what can go wrong in risky biopharma equities. The post Allakos Is a Cautionary Tale of Biopharmaceutical Investin...

8 months ago - InvestorPlace

Why Allakos Stock Plummeted 87.5% in the Last Month of 2021

The biotech stock is now down roughly 93% over the last year.

8 months ago - The Motley Fool

After a Clinical-Data Bombshell, Allakos Might Actually Be a Buy

After a well-publicized clinical-data letdown, it may be time to go long as the worst-case scenario has already been priced into ALLK stock. The post After a Clinical-Data Bombshell, Allakos Might Actua...

8 months ago - InvestorPlace

Down 86.1% in 4 Weeks, Here's Why Allakos Inc. (ALLK) Looks Ripe for a Turnaround

Allakos Inc. (ALLK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimate...

8 months ago - Zacks Investment Research

Allakos Inc. down 80% after announcing topline phase III results from its Enigma II clinical study

Allakos Inc (NASDAQ: ALLK) announced its results from Enigma II, Phase III placebo-controlled, double-blind clinical research of lirentelimab on people battling EG (eosinophilic gastritis) and went up b...

9 months ago - Invezz

Why Allakos Shares Are Plummeting Today

Allakos Inc (NASDAQ: ALLK) is trading significantly lower Wednesday after the company announced ENIGMA 2 and KRYPTOS studies did not achieve statistical significance on the patient reported symptomatic ...

9 months ago - Benzinga

ALLK Stock Alert: Why Is Allakos Absolutely Plunging Today?

Allakos' recent study results have sent ALLK stock straight to the bottom. Here's what investors should know right now.

9 months ago - InvestorPlace

Why Allakos Stock Is Crashing Today

The company announced disappointing results from two clinical studies.

9 months ago - The Motley Fool